<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852409</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG6001</org_study_id>
    <nct_id>NCT01852409</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites</brief_title>
  <official_title>Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant ascites often has a profound impact on the quality of life of cancer patients.&#xD;
      Current treatments,including dietary, medical, and procedural are often temporary and&#xD;
      unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab&#xD;
      for the palliation of malignant ascites might be a novel choice for refractory malignant&#xD;
      ascites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the treatment in the hospital,an expected average of 1 week</time_frame>
    <description>participants will be followed for the duration of hospital stay, an expected average of 1 week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 week</time_frame>
    <description>during the treatment in the hosptital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 week</time_frame>
    <description>ultrasound will be performed every week for efficacy evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure(TTF)</measure>
    <time_frame>1 month</time_frame>
    <description>the follow-up visit of time to TTF will be performed every 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to death(TTD)</measure>
    <time_frame>2 months</time_frame>
    <description>TTD means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 2 months till death or lost</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Refractory Malignant Ascites</condition>
  <arm_group>
    <arm_group_label>bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form;&#xD;
&#xD;
          2. Histologically or cytologically confirmed non-squamous cell carcinoma，including&#xD;
             colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, bile duct&#xD;
             cancer, ovarian cancer, peritoneal primary tumor;Ascites were diagnosed by ultrasound&#xD;
             or CT and confirmed malignant ascites by cytology;&#xD;
&#xD;
          3. failed to standard systemic therapy and / or no appropriate treatment for the&#xD;
             treatment for malignant ascites&#xD;
&#xD;
          4. Age 18-70 years;&#xD;
&#xD;
          5. Performance Status- Eastern Cooperative Oncology Group (ECOG)≤2;&#xD;
&#xD;
          6. Life expectancy of at least 8 weeks;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. systematic anti-cancer therapy, including chemotherapy (intraperitoneal chemotherapy),&#xD;
             radiation therapy, immunotherapy, biological or hormone therapy performed within 2&#xD;
             weeks;&#xD;
&#xD;
          2. tyrosine kinase inhibitors or monoclonal antibodies of anti-vascular endothelial&#xD;
             growth factor (VEGF) performed within 4 weeks;&#xD;
&#xD;
          3. Laboratory tests:Absolute neutrophil count&lt;1.0x109/L,Platelet count&lt;75x&#xD;
             109/L,Hemoglobin&lt;8g/dl,PT-INR≥1.5 times upper limit of normal (ULN);Bilirubin≥2 x&#xD;
             ULN,AST and ALT≥2.5 times ULN(no liver metastasis),≥5 times ULN(with liver&#xD;
             metastasis)Creatinine≥1.5 times ULN or calculated creatinine clearance, using the&#xD;
             Cockcroft-Gault formula,&lt;40 mL/min;&#xD;
&#xD;
          4. uncontrolled hypertension:systolic pressure ≥160 mmHg,or diastolic pressure≥100mmHg&#xD;
&#xD;
          5. Known history of severe heart disease,uncontrolled or symptomatic angina, congestive&#xD;
             heart failure,clinically significant arrhythmias,myocardial infarction within six&#xD;
             months;&#xD;
&#xD;
          6. active (severe or uncontrolled) bleeding (hemorrhage within 3 months&gt; 30 ml),&#xD;
             hemoptysis (fresh blood, 4 weeks&gt; 5 ml), bloody ascites&#xD;
&#xD;
          7. thrombosis, tumor thrombus events (including arterial/venous thrombosis, tumor&#xD;
             thrombosis, pulmonary embolism, transient ischemic attack)within 12 months;&#xD;
&#xD;
          8. Portal hypertensive disease or severe liver disease, including various types of&#xD;
             cirrhosis, obstructive jaundice;&#xD;
&#xD;
          9. concurrent gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative&#xD;
             colitis and other gastrointestinal diseases according to investigators' determination&#xD;
             that may cause gastrointestinal bleeding or perforation;&#xD;
&#xD;
         10. concurrent severe respiratory disease, or chronic therapy with oxygen or&#xD;
             corticosteroids, such as chronic obstructive pulmonary disease, interstitial lung&#xD;
             disease, etc.&#xD;
&#xD;
         11. Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities&#xD;
             greater than grade 2 or not recovered from surgery;&#xD;
&#xD;
         12. Symptomatic brain metastasis;&#xD;
&#xD;
         13. Uncontrolled systemic disease,such as infection,unstable diabetes mellitus,etc;&#xD;
&#xD;
         14. Active infection of HIV、HBV、HCV；&#xD;
&#xD;
         15. Major surgery within 4 weeks of start of study treatment, without complete recovery.&#xD;
&#xD;
         16. Pregnant or lactating women.Negative serum pregnancy test (For women of childbearing&#xD;
             potential);Fertile patients must use effective contraception.&#xD;
&#xD;
         17. Dementia, altered mental status, or any psychiatric condition that would prevent the&#xD;
             understanding or rendering of ICF;&#xD;
&#xD;
         18. Received any investigational drug treatment within 4 weeks of start of study&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Shen, M.D.</last_name>
    <phone>861088196561</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jifang Gong, M.D.</last_name>
    <phone>861088196561</phone>
    <email>gongjifang@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, M.D.</last_name>
      <phone>861088196561</phone>
      <email>lin100@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jifang Gong, M.D.</last_name>
      <phone>861088196561</phone>
      <email>gongjifang@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <last_update_submitted>May 19, 2013</last_update_submitted>
  <last_update_submitted_qc>May 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <keyword>refractory malignant ascites</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>intraperitoneal</keyword>
  <keyword>phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

